<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02638493</url>
  </required_header>
  <id_info>
    <org_study_id>15-2767</org_study_id>
    <secondary_id>R01DK108424-01</secondary_id>
    <nct_id>NCT02638493</nct_id>
  </id_info>
  <brief_title>The Compartmental Biology of HIV in the Male Genital Tract</brief_title>
  <official_title>IGHID 11526 - The Compartmental Biology of HIV in the Male Genital Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Male participants taking tenofovir-emtricitabine (TDF/FTC) will provide semen and blood
      samples which will be analyzed to better understand the pharmacology of antiretroviral
      therapy in the male genital tract.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      8 HIV positive men taking TDF/FTC and 8 HIV negative men taking TDF/FTC as pre-exposure
      prophylaxis will provide multiple semen and blood samples during a 48-hour inpatient visit. 8
      HIV positive men taking TAF (tenofovir alafenamide) will provide multiple semen and blood
      samples during a 48-hour inpatient visit.

      Participants will take part in the study for approximately two months. After the screening
      visit, there is one 2 day overnight visit for intensive PK/PD
      (pharmacokinetic/pharmacodynamic) sampling. The investigators will study drug concentrations
      and intracellular endogenous nucleotide concentrations (dATP and dCTP) in seminal plasma and
      (where appropriate) seminal cells.

      Samples will be analyzed through the use of novel laboratory methods to determine the seminal
      plasma and seminal cell concentrations of tenofovir and emtricitabine. New technologies will
      be used to better understand compartmental and intracellular antiretroviral pharmacology of
      nucleoside/tide reverse transcriptase inhibitors. Pharmacokinetic modeling will be used to
      estimate the primary outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Semen Clearance (CL) of Tenofovir</measure>
    <time_frame>Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose</time_frame>
    <description>Samples will be analyzed for drug concentrations at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate clearance from semen from a 300mg dose of tenofovir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Semen Clearance (CL) of Emtricitabine</measure>
    <time_frame>Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose</time_frame>
    <description>Samples will be analyzed for drug concentration at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate clearance from semen from a 200mg dose of emtricitabine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Semen Clearance (CL) of Tenofovir Diphosphate</measure>
    <time_frame>Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose</time_frame>
    <description>Samples will be analyzed for drug concentration at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate the clearance of tenofovir diphosphate, an intracellular metabolite of tenofovir, from seminal mononuclear cells, following a 300mg dose of tenofovir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Semen Clearance (CL) of Emtricitabine Triphosphate</measure>
    <time_frame>Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose</time_frame>
    <description>Samples will be analyzed for drug concentration at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate the clearance of emtricitabine triphosphate, an intracellular metabolite of emtricitabine, from seminal mononuclear cells, following a 200mg dose of emtricitabine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peripheral Blood Mononuclear Cell (PBMC) Clearance (CL) of Tenofovir Diphosphate</measure>
    <time_frame>Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose</time_frame>
    <description>Samples will be analyzed for drug concentration at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate the clearance of tenofovir diphosphate, an intracellular metabolite of tenofovir, from peripheral blood mononuclear cells, following a 300mg dose of tenofovir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peripheral Blood Mononuclear Cell (PBMC) Clearance (CL) of Emtricitabine Triphosphate</measure>
    <time_frame>Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose</time_frame>
    <description>Samples will be analyzed for drug concentration at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate the clearance of emtricitabine triphosphate, an intracellular metabolite of emtricitabine, from peripheral blood mononuclear cells, following a 200mg dose of emtricitabine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tenofovir Diphosphate (TFVdp)/Deoxyadenosine Triphosphate (dATP) Ratio in Seminal Mononuclear Cells</measure>
    <time_frame>Average concentration in a 24 hour dosing interval</time_frame>
    <description>dATP concentrations in seminal mononuclear cells will be measured and compared to tenofovir diphosphate concentrations, using a ratio, and summarized descriptively for each subject, as well as across subjects. As the six seminal cell samples collected per man were pooled for analysis due to low cell recovery, a single ratio value per participant was calculated and summarized by study arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emtricitabine Triphosphate (FTCtp)/Deoxyadenosine Triphosphate (dCTP) Ratio in Seminal Mononuclear Cells</measure>
    <time_frame>Average concentration in a 24 hour dosing interval</time_frame>
    <description>dCTP concentrations in seminal mononuclear cells will be measured and compared to emtricitabine triphosphate concentrations, using a ratio, and summarized descriptively for each subject, as well as across subjects. As the six seminal cell samples collected per man were pooled for analysis due to low cell recovery, a single ratio value per participant was calculated and summarized by study arm.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">26</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <condition>Virus Shedding</condition>
  <arm_group>
    <arm_group_label>HIV positive TDF/FTC</arm_group_label>
    <description>8 HIV positive men taking TDF/FTC as treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV negative</arm_group_label>
    <description>8 HIV negative men taking TDF/FTC as pre-exposure prophylaxis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV Positive TAF</arm_group_label>
    <description>8 HIV positive men taking TAF as treatment</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and semen samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV positive and HIV negative men taking TDF/FTC once daily, HIV positive men taking
        TAF/FTC once daily
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Born male between the ages of 18 and 60

          -  HIV positive taking TDF/FTC (and a third drug) as treatment; or HIV negative men
             receiving TDF/FTC as pre-exposure prophylaxis; HIV positive men taking tenofovir
             alafenamide

          -  if on routine treatment must have been taking medication for at least 3 months and
             adherence to medication as assessed by blood plasma HIV RNA less than 50 copies per
             mL.

          -  documentation of at least 80% adherence to antiretroviral (ART) regimen, through
             clinician or self-report, with no missed doses in the 3 days prior to the inpatient
             visit.

          -  willing and able to comply with scheduled visits, treatment plan, laboratory tests,
             and other trial procedures.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurologic
             disease that would pose unnecessary risk or interfere with study results.

          -  unwilling or unable to abstain from sexual activity 72 hours prior to overnight
             sampling visit

          -  unlikely to remain on current drug regimen during study period

          -  anemia that precludes blood donation

          -  unable to provide semen specimen

          -  current receipt of other medications that may affect endogenous nucleotide
             concentrations, such as additional HIV nucleoside reverse transcriptase inhibitors,
             ribavirin, or adefovir
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Dumond, PharmD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.unc.edu</url>
    <description>University of North Carolina website</description>
  </link>
  <reference>
    <citation>Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol. 2004 Jan;2(1):33-42. Review.</citation>
    <PMID>15035007</PMID>
  </reference>
  <reference>
    <citation>Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med. 2007 Apr 17;146(8):591-601. Review.</citation>
    <PMID>17438318</PMID>
  </reference>
  <reference>
    <citation>Anderson DJ, Politch JA, Nadolski AM, Blaskewicz CD, Pudney J, Mayer KH. Targeting Trojan Horse leukocytes for HIV prevention. AIDS. 2010 Jan 16;24(2):163-87. doi: 10.1097/QAD.0b013e32833424c8. Review.</citation>
    <PMID>20010071</PMID>
  </reference>
  <reference>
    <citation>Joseph SB, Swanstrom R, Kashuba AD, Cohen MS. Bottlenecks in HIV-1 transmission: insights from the study of founder viruses. Nat Rev Microbiol. 2015 Jul;13(7):414-25. doi: 10.1038/nrmicro3471. Epub 2015 Jun 8. Review.</citation>
    <PMID>26052661</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2015</study_first_submitted>
  <study_first_submitted_qc>December 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2015</study_first_posted>
  <results_first_submitted>March 2, 2017</results_first_submitted>
  <results_first_submitted_qc>April 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 24, 2017</results_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Julie Dumond, PharmD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>tenofovir-emtricitabine</keyword>
  <keyword>antiretroviral therapy</keyword>
  <keyword>Prevention</keyword>
  <keyword>tenofovir alafenamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All participants were recruited at the University of North Carolina at Chapel Hill and surrounding areas, through Institutional Review Board (IRB)-approved advertisements.</recruitment_details>
      <pre_assignment_details>Participants interested in the study were pre-screened for eligibility using an IRB-approved questionnaire.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>HIV Positive TDF/FTC</title>
          <description>8 HIV positive men taking TDF/FTC (Tenofovir Disoproxil Fumarate/Emtricitabine) as treatment</description>
        </group>
        <group group_id="P2">
          <title>HIV Negative</title>
          <description>8 HIV negative men taking TDF/FTC (Tenofovir Disoproxil Fumarate/Emtricitabine) as pre-exposure prophylaxis</description>
        </group>
        <group group_id="P3">
          <title>HIV Positive TAF</title>
          <description>8 HIV positive men taking TAF (Tenofovir Alafenamide) as treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10">Two men were not able to provide semen samples, and thus were replaced</participants>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Inability to provide semen samples</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HIV Positive TDF/FTC</title>
          <description>8 HIV positive men taking TDF/FTC as treatment</description>
        </group>
        <group group_id="B2">
          <title>HIV Negative</title>
          <description>8 HIV negative men taking TDF/FTC as pre-exposure prophylaxis</description>
        </group>
        <group group_id="B3">
          <title>HIV Positive TAF</title>
          <description>8 HIV positive men taking TAF as treatment</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.5" lower_limit="33" upper_limit="41"/>
                    <measurement group_id="B2" value="30.5" lower_limit="19" upper_limit="39"/>
                    <measurement group_id="B3" value="45.5" lower_limit="34" upper_limit="52"/>
                    <measurement group_id="B4" value="36.5" lower_limit="19" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Semen Clearance (CL) of Tenofovir</title>
        <description>Samples will be analyzed for drug concentrations at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate clearance from semen from a 300mg dose of tenofovir.</description>
        <time_frame>Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV Positive TDF/FTC</title>
            <description>8 HIV positive men taking TDF/FTC as treatment</description>
          </group>
          <group group_id="O2">
            <title>HIV Negative</title>
            <description>8 HIV negative men taking TDF/FTC as pre-exposure prophylaxis</description>
          </group>
          <group group_id="O3">
            <title>HIV Positive TAF</title>
            <description>8 HIV positive men taking TAF as treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Semen Clearance (CL) of Tenofovir</title>
          <description>Samples will be analyzed for drug concentrations at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate clearance from semen from a 300mg dose of tenofovir.</description>
          <units>L/hr</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.88" lower_limit="18.86" upper_limit="65.26"/>
                    <measurement group_id="O2" value="51.21" lower_limit="19.18" upper_limit="77.79"/>
                    <measurement group_id="O3" value="5.65" lower_limit="3.23" upper_limit="7.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Semen Clearance (CL) of Emtricitabine</title>
        <description>Samples will be analyzed for drug concentration at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate clearance from semen from a 200mg dose of emtricitabine.</description>
        <time_frame>Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV Positive TDF/FTC</title>
            <description>8 HIV positive men taking TDF/FTC as treatment</description>
          </group>
          <group group_id="O2">
            <title>HIV Negative</title>
            <description>8 HIV negative men taking TDF/FTC as pre-exposure prophylaxis</description>
          </group>
          <group group_id="O3">
            <title>HIV Positive TAF</title>
            <description>8 HIV positive men taking TAF as treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Semen Clearance (CL) of Emtricitabine</title>
          <description>Samples will be analyzed for drug concentration at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate clearance from semen from a 200mg dose of emtricitabine.</description>
          <units>L/hr</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.91" lower_limit="5.43" upper_limit="8.28"/>
                    <measurement group_id="O2" value="8.72" lower_limit="4.95" upper_limit="12.30"/>
                    <measurement group_id="O3" value="7.12" lower_limit="3.91" upper_limit="11.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Semen Clearance (CL) of Tenofovir Diphosphate</title>
        <description>Samples will be analyzed for drug concentration at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate the clearance of tenofovir diphosphate, an intracellular metabolite of tenofovir, from seminal mononuclear cells, following a 300mg dose of tenofovir.</description>
        <time_frame>Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV Positive TDF/FTC</title>
            <description>8 HIV positive men taking TDF/FTC as treatment</description>
          </group>
          <group group_id="O2">
            <title>HIV Negative</title>
            <description>8 HIV negative men taking TDF/FTC as pre-exposure prophylaxis</description>
          </group>
          <group group_id="O3">
            <title>HIV Positive TAF</title>
            <description>8 HIV positive men taking TAF as treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Semen Clearance (CL) of Tenofovir Diphosphate</title>
          <description>Samples will be analyzed for drug concentration at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate the clearance of tenofovir diphosphate, an intracellular metabolite of tenofovir, from seminal mononuclear cells, following a 300mg dose of tenofovir.</description>
          <units>fmol/10x6 cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="5.7" upper_limit="88"/>
                    <measurement group_id="O2" value="21" lower_limit="4.2" upper_limit="91"/>
                    <measurement group_id="O3" value="35" lower_limit="24" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Semen Clearance (CL) of Emtricitabine Triphosphate</title>
        <description>Samples will be analyzed for drug concentration at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate the clearance of emtricitabine triphosphate, an intracellular metabolite of emtricitabine, from seminal mononuclear cells, following a 200mg dose of emtricitabine.</description>
        <time_frame>Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose</time_frame>
        <population>Semen (SMC) Steady State Concentrations (Css,ave) of Emtricitabine Triphosphate</population>
        <group_list>
          <group group_id="O1">
            <title>HIV Positive TDF/FTC</title>
            <description>8 HIV positive men taking TDF/FTC as treatment</description>
          </group>
          <group group_id="O2">
            <title>HIV Negative</title>
            <description>8 HIV negative men taking TDF/FTC as pre-exposure prophylaxis</description>
          </group>
          <group group_id="O3">
            <title>HIV Positive TAF</title>
            <description>8 HIV positive men taking TAF as treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Semen Clearance (CL) of Emtricitabine Triphosphate</title>
          <description>Samples will be analyzed for drug concentration at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate the clearance of emtricitabine triphosphate, an intracellular metabolite of emtricitabine, from seminal mononuclear cells, following a 200mg dose of emtricitabine.</description>
          <population>Semen (SMC) Steady State Concentrations (Css,ave) of Emtricitabine Triphosphate</population>
          <units>fmol/10 E6 cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="22" upper_limit="119"/>
                    <measurement group_id="O2" value="90" lower_limit="34" upper_limit="193"/>
                    <measurement group_id="O3" value="179" lower_limit="108" upper_limit="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peripheral Blood Mononuclear Cell (PBMC) Clearance (CL) of Tenofovir Diphosphate</title>
        <description>Samples will be analyzed for drug concentration at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate the clearance of tenofovir diphosphate, an intracellular metabolite of tenofovir, from peripheral blood mononuclear cells, following a 300mg dose of tenofovir.</description>
        <time_frame>Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV Positive TDF/FTC</title>
            <description>8 HIV positive men taking TDF/FTC as treatment</description>
          </group>
          <group group_id="O2">
            <title>HIV Negative</title>
            <description>8 HIV negative men taking TDF/FTC as pre-exposure prophylaxis</description>
          </group>
          <group group_id="O3">
            <title>HIV Positive TAF</title>
            <description>8 HIV positive men taking TAF as treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Peripheral Blood Mononuclear Cell (PBMC) Clearance (CL) of Tenofovir Diphosphate</title>
          <description>Samples will be analyzed for drug concentration at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate the clearance of tenofovir diphosphate, an intracellular metabolite of tenofovir, from peripheral blood mononuclear cells, following a 300mg dose of tenofovir.</description>
          <units>fmol/10 E6 cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174" lower_limit="115" upper_limit="239"/>
                    <measurement group_id="O2" value="119" lower_limit="76" upper_limit="174"/>
                    <measurement group_id="O3" value="935" lower_limit="684" upper_limit="2024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peripheral Blood Mononuclear Cell (PBMC) Clearance (CL) of Emtricitabine Triphosphate</title>
        <description>Samples will be analyzed for drug concentration at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate the clearance of emtricitabine triphosphate, an intracellular metabolite of emtricitabine, from peripheral blood mononuclear cells, following a 200mg dose of emtricitabine.</description>
        <time_frame>Samples collected at 3, 6, 9, 12, 18 and 24 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV Positive TDF/FTC</title>
            <description>8 HIV positive men taking TDF/FTC as treatment</description>
          </group>
          <group group_id="O2">
            <title>HIV Negative</title>
            <description>8 HIV negative men taking TDF/FTC as pre-exposure prophylaxis</description>
          </group>
          <group group_id="O3">
            <title>HIV Positive TAF</title>
            <description>8 HIV positive men taking TAF as treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Peripheral Blood Mononuclear Cell (PBMC) Clearance (CL) of Emtricitabine Triphosphate</title>
          <description>Samples will be analyzed for drug concentration at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate the clearance of emtricitabine triphosphate, an intracellular metabolite of emtricitabine, from peripheral blood mononuclear cells, following a 200mg dose of emtricitabine.</description>
          <units>fmol/10 E6 cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6038" lower_limit="4465" upper_limit="10088"/>
                    <measurement group_id="O2" value="6135" lower_limit="3889" upper_limit="8303"/>
                    <measurement group_id="O3" value="8242" lower_limit="5602" upper_limit="13480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tenofovir Diphosphate (TFVdp)/Deoxyadenosine Triphosphate (dATP) Ratio in Seminal Mononuclear Cells</title>
        <description>dATP concentrations in seminal mononuclear cells will be measured and compared to tenofovir diphosphate concentrations, using a ratio, and summarized descriptively for each subject, as well as across subjects. As the six seminal cell samples collected per man were pooled for analysis due to low cell recovery, a single ratio value per participant was calculated and summarized by study arm.</description>
        <time_frame>Average concentration in a 24 hour dosing interval</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV Positive TDF/FTC</title>
            <description>8 HIV positive men taking TDF/FTC as treatment</description>
          </group>
          <group group_id="O2">
            <title>HIV Negative</title>
            <description>8 HIV negative men taking TDF/FTC as pre-exposure prophylaxis</description>
          </group>
          <group group_id="O3">
            <title>HIV Positive TAF</title>
            <description>8 HIV positive men taking TAF as treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Tenofovir Diphosphate (TFVdp)/Deoxyadenosine Triphosphate (dATP) Ratio in Seminal Mononuclear Cells</title>
          <description>dATP concentrations in seminal mononuclear cells will be measured and compared to tenofovir diphosphate concentrations, using a ratio, and summarized descriptively for each subject, as well as across subjects. As the six seminal cell samples collected per man were pooled for analysis due to low cell recovery, a single ratio value per participant was calculated and summarized by study arm.</description>
          <units>TFVdp:dATP ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.43" upper_limit="1.54"/>
                    <measurement group_id="O2" value="0.66" lower_limit="0.22" upper_limit="1.21"/>
                    <measurement group_id="O3" value="1.10" lower_limit="0.42" upper_limit="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Emtricitabine Triphosphate (FTCtp)/Deoxyadenosine Triphosphate (dCTP) Ratio in Seminal Mononuclear Cells</title>
        <description>dCTP concentrations in seminal mononuclear cells will be measured and compared to emtricitabine triphosphate concentrations, using a ratio, and summarized descriptively for each subject, as well as across subjects. As the six seminal cell samples collected per man were pooled for analysis due to low cell recovery, a single ratio value per participant was calculated and summarized by study arm.</description>
        <time_frame>Average concentration in a 24 hour dosing interval</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV Positive TDF/FTC</title>
            <description>8 HIV positive men taking TDF/FTC as treatment</description>
          </group>
          <group group_id="O2">
            <title>HIV Negative</title>
            <description>8 HIV negative men taking TDF/FTC as pre-exposure prophylaxis</description>
          </group>
          <group group_id="O3">
            <title>HIV Positive TAF</title>
            <description>8 HIV positive men taking TAF as treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Emtricitabine Triphosphate (FTCtp)/Deoxyadenosine Triphosphate (dCTP) Ratio in Seminal Mononuclear Cells</title>
          <description>dCTP concentrations in seminal mononuclear cells will be measured and compared to emtricitabine triphosphate concentrations, using a ratio, and summarized descriptively for each subject, as well as across subjects. As the six seminal cell samples collected per man were pooled for analysis due to low cell recovery, a single ratio value per participant was calculated and summarized by study arm.</description>
          <units>FTCtp:dCTP ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" lower_limit="0.38" upper_limit="1.14"/>
                    <measurement group_id="O2" value="0.96" lower_limit="0.39" upper_limit="1.85"/>
                    <measurement group_id="O3" value="3.81" lower_limit="2.30" upper_limit="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time of informed consent, until end of study enrollment.</time_frame>
      <desc>does not differ</desc>
      <group_list>
        <group group_id="E1">
          <title>HIV Positive TDF/FTC</title>
          <description>8 HIV positive men taking TDF/FTC as treatment</description>
        </group>
        <group group_id="E2">
          <title>HIV Negative</title>
          <description>8 HIV negative men taking TDF/FTC as pre-exposure prophylaxis</description>
        </group>
        <group group_id="E3">
          <title>HIV Positive TAF</title>
          <description>8 HIV positive men taking TAF as treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Viral Pharyngitis</sub_title>
                <description>Sore throat and temperature reported, rapid strep sent, result negative.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Penile skin irritation</sub_title>
                <description>Mild skin irritation/soreness following sample</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Julie B. Dumond, PharmD, MS, BCPS, AAHIVP</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>919-966-5017</phone>
      <email>jdumond@unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

